e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response

Simple item page
dc.contributor.authorMarcé, Sílvia
dc.contributor.authorEscribano Serrat, Silvia
dc.contributor.authorAnguita Mandly, Eduardo Luis
dc.contributor.authorZamora, Lurdes
dc.date.accessioned2024-06-28T07:52:03Z
dc.date.available2024-06-28T07:52:03Z
dc.date.issued2024-01-29
dc.description.abstracte13a2 and e14a2 are the most frequent transcript types of the BCR::ABL1 fusion gene in chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to achieve sustained deep molecular response (DMR) in order to discontinue TKI treatment and remain in the so-called treatment-free remission (TFR) phase, but biological factors associated with these goals are not well established. This study aimed to determine the effect of transcript type on TFR in patients receiving frontline treatment with imatinib (IM) or second-generation TKI (2G-TKI). Patients treated at least 119 months with IM presented less post-discontinuation relapse than those that discontinued IM before 119 months (p = 0.005). In addition, cases with the e14a2 transcript type treated at least 119 months with IM presented a better TFR (p = 0.024). On the other hand, the type of transcript did not affect the cytogenetic or molecular response in 2G-TKI treated patients; however, the use of 2G-TKI may be associated with higher and earlier DMR in patients with the e14a2 transcript.
dc.description.departmentDepto. de Medicina
dc.description.facultyFac. de Medicina
dc.description.fundingtypeDescuento UCM
dc.description.refereedTRUE
dc.description.sponsorshipGeneralitat de Catalunya
dc.description.sponsorshipJosep Carreras International Foundation
dc.description.sponsorship“La Caixa” Foundation
dc.description.statuspub
dc.identifier.citationMarcé S, Méndez A, Xicoy B, Estrada N, Cabezón M, Sturla AL, García MR, Angona A, Amat P, Escribano Serrat S, et al. e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response. Journal of Clinical Medicine. 2024; 13(3):779. https://doi.org/10.3390/jcm13030779
dc.identifier.doi10.3390/jcm13030779
dc.identifier.issn2077-0383
dc.identifier.officialurlhttps://doi.org/10.3390/jcm13030779
dc.identifier.urihttps://hdl.handle.net/20.500.14352/105332
dc.issue.number3
dc.journal.titleJournal of clinical medicine
dc.language.isoeng
dc.page.initial779
dc.publisherMDPI
dc.relation.projectIDinfo:eu-repo/grantAgreement/CAT/SGR/288
dc.rightsAttribution 4.0 Internationalen
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subject.cdu616.15-006.4
dc.subject.keywordHematología
dc.subject.keywordLeucemia mieloide crónica
dc.subject.keywordBiología Molecular
dc.subject.ucmHematología
dc.subject.unesco3205.04 Hematología
dc.subject.unesco2415 Biología Molecular
dc.titlee14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response
dc.typejournal article
dc.type.hasVersionVoR
dc.volume.number13
dspace.entity.typePublication
relation.isAuthorOfPublicationaa41c8cb-98ce-401a-99fb-32d3a2f96f00
relation.isAuthorOfPublication.latestForDiscoveryaa41c8cb-98ce-401a-99fb-32d3a2f96f00
Download
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
2024_e14a2 Transcript Favors Treatment-Free Remission in Chronic.pdf
Size:
2.13 MB
Format:
Adobe Portable Document Format
downoload Download
Collections
Artículos